San Francisco startup Structure Therapeutics is additionally focusing on an oral, at the time-day-to-day GLP-1 drug called GSBR-1290—the drug surpassed Wall Avenue’s expectations in June every time a mid-stage research confirmed ordinary weight loss of close to six% and it options to start out An additional mid-stage trial to the tip of this yr